Rare Disease and Orphan Drug Development
There are 7,000 rare diseases impacting 350 million patients worldwide, yet only 300 of these…
CertaraAugust 3, 2016
Model-based Meta-analysis: An Innovative Methodology Comes of Age
MBMA integrates internal and external drug development data to inform proprietary commercial and R&D decisions.…
CertaraJuly 14, 2016
How Does the In Vivo Biliary Elimination of Drugs Change with Age? Evidence from In Vitro and Clinical Data Using a Systems Pharmacology Approach
Information on the developmental changes in biliary excretion (BE) of drugs is sparse. The aims…
CertaraJuly 1, 2016
Considering Age Variation When Coining Drugs as High Versus Low Hepatic Extraction Ratio
The hepatic extraction ratio (EH) is commonly considered an "inherent attribute" of drug. It determines…
CertaraJuly 1, 2016
Pharmacokinetics and Tissue Elimination of Funixin in Veal Calves
OBJECTIVE To describe plasma pharmacokinetic parameters and tissue elimination of flunixin in veal calves. ANIMALS…
CertaraJune 1, 2016
Development of a Permeability-limited Model of the Human Brain and Cerebrospinal Fluid (CSF) to Integrate Known Physiological and Biological Knowledge: Estimating Time Varying CSF Drug Concentrations and Their Variability Using In Vitro Data
A 4-compartment permeability-limited brain (4Brain) model consisting of brain blood, brain mass, cranial and spinal…
CertaraJune 1, 2016
